Clinical Implication of EGF A61G Polymorphism in the Risk of Non Small Cell Lung Adenocarcinoma Patients: A Case Control Study.

Mirza Masroor,Alpana Saxena,Anant Mohan,Rashid Mir,Jain Amit,Pc Ray,Y Prasant,A Imtiyaz,Jamsheed Javid,Z Mariyam

doi:10.7314/apjcp.2015.16.17.7529

Mirza Masroor, Alpana Saxena + Show 8 more

Open Access

https://doi.org/10.7314/apjcp.2015.16.17.7529

Copy DOI

Abstract

The epidermal growth factor (EGF) plays important roles in non-small cell lung cancer (NSCLC) susceptibility and functional polymorphism in the EGF (+61A/G) gene has been linked to increased risk of NSCLC. This study aimed to evaluate the role of the EGF +61A/G polymorphism in risk of NSCLC adenocarcinoma (ADC) occurrence and survival in an Indian population. This case- control study included 100 histopathologically confirmed NSCLC (ADC) patients and 100 healthy controls. EGF (A61G) was genotyped by AS-PCR to elucidate putative associations with clinical outcomes. The association of the polymorphism with the survival of NSCLC patients was estimated by Kaplan-Meier curves. It was found that EGF 61AG heterozygous and GG homozygous genotype is significantly associated with increased risk of NSCLC (ADC) occurrence compared to AA genotype, [OR 2.61 (1.31-5.18) and 3.25 (1.31-8.06), RR 1.51(1.15-2.0) and 1.72 (1.08-2.73) and RD 23.2 (6.90-39.5) and 28.53(7.0-50.1) for heterozygous AG (p=0.005) and homozygous GG (p=0.009)]. Patients homozygous for the G allele exhibited a significantly poor overall survival. The median survival time for patients with EGF 61 AA, AG, and GG genotypes was 10.5, 7.4, and 7.1 months (p=0.02), respectively. NSCLC (ADC) patients with GG + AG exhibited 7.3 months median survival compared to the AA genotype (p=0.009). The present study revealed that the EGF A61G genotype may be a novel independent prognostic marker to identify patients at higher risk of occurrence and an unfavourable clinical outcome.

Highlights

Non-small cell lung cancer (NSCLC) is the major cancer killer disease worldwide in both males and females accounting for more than1.2 million deaths each year (Alberg et al, 2005)
The present data explored the association of epidermal growth factor (EGF) (A61G) polymorphism with risk and unfavourable clinical outcome of non-small cell lung cancer
The first report from Indian population, suggested that homozygous EGF (+61)GG genotype is strongly associated with the risk of developing non-small cell lung cancer (NSCLC) ADC with approximately more than 3 fold increase than homozygous EGF (+61)AA genotype

Summary

Introduction

Non-small cell lung cancer (NSCLC) is the major cancer killer disease worldwide in both males and females accounting for more than1.2 million deaths each year (Alberg et al, 2005). The epidermal growth factor (EGF) plays important roles in non-small cell lung cancer (NSCLC) susceptibility and functional polymorphism in the EGF (+61A/G) gene has been linked to increased risk of NSCLC. This study aimed to evaluate the role of the EGF +61A/G polymorphism in risk of NSCLC adenocarcinoma (ADC) occurrence and survival in an Indian population. Results: It was found that EGF 61AG heterozygous and GG homozygous genotype is significantly associated with increased risk of NSCLC (ADC) occurrence compared to AA genotype, [OR 2.61 (1.31-5.18) and 3.25 (1.31-8.06), RR 1.51(1.15-2.0) and 1.72 (1.08-2.73) and RD 23.2 (6.90-39.5) and 28.53(7.0-50.1) for heterozygous AG (p=0.005) and homozygous GG (p=0.009)]. NSCLC (ADC) patients with GG + AG exhibited 7.3 months median survival compared to the AA genotype (p=0.009). Conclusions: The present study revealed that the EGF A61G genotype may be a novel independent prognostic marker to identify patients at higher risk of occurrence and an unfavourable clinical outcome

Objectives

Methods

Results

Conclusion